Category: In Focus

Topical Alpha-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?

by James Q. Del Rosso, DO, FAOCD, FAAD Dr. Del Rosso is Research Director at JDR Dermatology Research, Las Vegas, Nevada and at Henderson Dermatology Research in Henderson, Nevada; is Adjunct Clinical Professor (Dermatology) at ableouro University Nevada, Las Vegas, Nevada; and practices Dermatology and Cutaneous Surgery at Thomas Dermatology in Las Vegas, Nevada. J


A Closer Look at Seborrheic Keratoses: Patient Perspectives, Clinical Relevance, Medical Necessity, and Implications for Management

James Q. Del Rosso, DO, FAOCD, FAAD Research Director, JDR Dermatology Research and Private Dermatology Practice, Thomas Dermatology, Las Vegas, Nevada Disclosure: Dr. Del Rosso serves as a consultant to Aclaris Therapeutics, Inc. (Malvern, Pennsylvania) that  has a topical therapy for seborrheic keratosis under development. He also served as a consultant for and as the


Emerging Issues in Adult Female Acne

aJoshua A. Zeichner, MD; bHillary E. Baldwin, MD; cFran E. Cook-Bolden, MD; dLawrence F. Eichenfield, MD; dSheila Fallon-Friedlander, MD; eDavid A. Rodriguez, MD aMount Sinai Hospital, New York, New York bMorristown, New Jersey cSkin Specialty Dermatology, New York, New York dUniversity of California, Rady Children’s Hospital, San Diego, California eDermatology Associates/Research, Coral Gables, Florida; cRedwood


Oral Apremilast for the Treatment of Plaque Psoriasis

James Q. Del Rosso, DO; Leon Kircik, MD Disclosures (related to this manuscript): Dr. Del Rosso is a speaker, consultant, and/or researcher for Anacor, Aqua, Allergan, Bayer, Celgene, Galderma, LeoPharma, Novartis, Pharmaderm, Promius, SunPharma, and Valeant. Dr. Kircik is either a speaker, consultant, or investigator for Amgen, Anacor, Aqua, Allergan, Bayer, Celgene, Coherus, Eli Lilly,